Three big-time global fund managers got together for a panel discussion the other day focused on investment opportunities in big pharma companies and health care in general. For the most part, they are all concerned about over-regulation, expiring patents, and the last ten years during which innovation could have been more robust. If you are in the healthcare industry or work in big pharma, you’ll want to read their analysis, which is here.
But the good news is that the three fund managers — David Winters of Wintergreen Fund; Rajeev Bhaman, who has managed Oppenheimer Global since 2004; and Diana Strandberg of Dodge & Cox Global and Dodge & Cox International — agreed that emerging markets are very attractive right now:
…the three global managers agreed completely on a different issue: the appeal of emerging markets. They all think that growth rates in emerging markets will be much higher in coming years than in developed countries and that fund managers must seek the best ways to tap into that trend.
The article doesn’t say this, but doesn’t it stand to reason that if healthcare and pharma companies can tap into emerging markets, it could offset what might otherwise be seen as a lukewarm future for them?
GHS and Regulatory Labeling Challenges in the New Era 
